Oncology
Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the “Company”) is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat…
Read MoreExcerpt from the Press Release: SPRINGFIELD, Mo. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Fight Colorectal Cancer (Fight CRC), the nation’s leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back…
Read MoreExcerpt from the Press Release: MONMOUTH JUNCTION, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of ELU-001,…
Read MoreExcerpt from the Press Release: LAWRENCEVILLE, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 55 as treated patients randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data…
Read MoreExcerpt from the Press Release: MARLBOROUGH, Mass., July 19, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that the Phenoptics™ mIF solution was used in a multi-site study to demonstrate and validate an automated end-to-end workflow that characterizes PD-1/PD-L1 immune checkpoint signaling in tumor tissue samples. The paper…
Read MoreExcerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed in-vitro activity…
Read MoreExcerpt from the Press Release: CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for…
Read MoreExcerpt from the Article: One of the most common cancers among men in the United States, prostate cancer is second in prevalence only to skin cancer. Approximately 12.5 percent of men will be diagnosed with prostate cancer at some point during their lifetimes. Put another way, out of every 100 American men, approximately 13 will get prostate cancer during…
Read MoreExcerpt from the Press Release: BOSTON, July 15, 2021 /PRNewswire/ — COTA, Inc., an oncology real-world data and analytics company, announced a new research partnership with MedStar Health. COTA will support MedStar Health in its use of real-world data to accelerate scientific discovery and improve care for cancer patients. MedStar Health is the largest healthcare provider in the Maryland and Washington, D.C.,…
Read MoreExcerpt from the Article: In men who have prostate cancer, pairing active surveillance with prostate MRI is a more cost-effective approach to treatment over time than relying on active surveillance, repeated biopsy and prostate-specific antigen (PSA) tests. These findings, published July 14 in Radiology, come on the heels of additional research that indicates prostate MRI can…
Read More